Bridgepoint upgrades guidance after strong performance
The firm exceeded its €28bn fundraising target early, enhanced shareholder distribution, and revised long-term projections upward.
See the latest news and media coverage for Bridgepoint. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global middle-market alternative asset manager
bridgepointgroup.comLast updated
In short: Bridgepoint raised 2026 guidance after record first-half results and advanced major acquisition and aviation-investment plans.
The firm exceeded its €28bn fundraising target early, enhanced shareholder distribution, and revised long-term projections upward.
The unified brand combines over 550 pharmaceutical experts across commercial, medical and market access disciplines. It provides single access to expertise across the product lifecycle.
The fund exceeded its $5 billion target, reaching an increased hard cap amid strong global investor demand.
Assets under management rose 24.5% to $94.1bn, with €7.8bn deployed and €14bn raised. Over €8bn was returned to investors, and Bridgepoint Generations launched its first wealth product.
Bridgepoint Group plc (BPT.L) increased its guidance for 2026 EBITDA, due to exceptional fund performance in ECP V. The Group's 2026 Performance Related Earnings and...
An announcement from Bridgepoint Group Plc ( ) is now available. Bridgepoint Group plc has secured strong shareholder backing for its proposed acquisition of Kayne...
Bridgepoint and Astorg are considering selling Fenergo as dealmaking in the sector picks up, three people familiar with the matter said, with one saying the...
The U.S. Nuclear Regulatory Commission (NRC) issued an order approving the indirect transfer of control of Radioactive Materials License No. 39-35044-01, License Nos. DPR-43, DPR-73...
Track Bridgepoint and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Bridgepoint and other trending companies.